ZYUS Life Sciences Corporation
ZLSCF
$0.60
-$0.06-9.09%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 8.11% | 47.96% | 30.75% | -307.55% | 44.67% |
| Total Depreciation and Amortization | -6.71% | 18.57% | -22.13% | 485.46% | -32.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 282.81% | -95.89% | -89.43% | 462.55% | -105.88% |
| Change in Net Operating Assets | 127.90% | 363.51% | -182.16% | 1,519.65% | -384.07% |
| Cash from Operations | 82.91% | 91.23% | -62.26% | -54.20% | -299.34% |
| Capital Expenditure | 68.97% | 100.00% | 29.01% | 29.06% | 61.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 68.97% | -100.00% | 29.01% | 36.58% | 61.73% |
| Total Debt Issued | -- | -97.87% | -- | -100.00% | -100.00% |
| Total Debt Repaid | -371.32% | 97.28% | -459.02% | -111.39% | -197.84% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 281.33% | -98.03% | -114.32% | -115.27% | -125.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.76% | -100.81% | -525.76% | -5,852.93% | -11,985.19% |
